More Stories

Informist, Friday, May 8, 2026

--Biocon Jan-Mar consol net profit INR 1.26 bln

--Analysts saw Biocon Jan-Mar consol net profit at INR 2.12 bln

--Biocon Jan-Mar consol revenue INR 45.17 bln

--Analysts saw Biocon Jan-Mar consol revenue at INR 45.50 bln

--Biocon Jan-Mar consol net profit INR 1.26 bln vs INR 3.45 bln yr ago

--Biocon Jan-Mar consol revenue INR 45.17 bln vs INR 44.17 bln yr ago

--Biocon Jan-Mar net profit includes one-time cost INR 804 mln

--Biocon to pay INR 0.50 per share final dividend

--Biocon final dividend record date Jul 3

--Biocon FY26 consol net profit INR 3.86 bln vs INR 10.13 bln yr ago

--Biocon FY26 consol revenue INR 169.27 bln vs INR 152.62 bln yr ago

--Biocon Jan-Mar biosimilars revenue INR 27.56 bln vs INR 24.63 bln yr ago

--Biocon Jan-Mar generics sales INR 8.47 bln vs INR 10.48 bln yr ago

--Biocon Jan-Mar research svcs sales INR 10.37 bln vs INR 10.18 bln yr ago

--Biocon Jan-Mar consol EBITDA INR 10.73 bln vs INR 11.15 bln yr ago

--Biocon Jan-Mar consol EBITDA margin 23% vs 25% year ago

--Biocon Jan-Mar net R&D expenses at INR 2.77 bln vs INR 2.31 bln yr ago

By Rajesh Gajra

MUMBAI – Exceptional items proved to be a significant drag on the net profit performance of biopharmaceutical company Biocon Ltd. for the March quarter leading to a sharp drop of nearly 64% in consolidated net profit to INR 1.26 billion. There were over 3–4 exceptional items during the March quarter, which together accounted for net exceptional outgo of around INR 804 million.

Adjusted for exceptional items, Biocon's consolidated net profit in the March quarter fell 40% on year to INR 2.06 billion, and was below analysts' estimate of INR 2.12 billion. The fall in net profit was driven by a drop in profit before tax of the company's generics and contract research, development, and manufacturing organisation segments. The bottom line performance was partially salvaged by a jump up in the profit before tax of its third key segment of biosimilars for the March quarter.

The company's consolidated revenue from operations for the March quarter went up by just 2.3% on year to INR 45.17 billion, and was largely in line with the Street view of INR 45.50 billion. The generics segment took a big hit with revenue falling 19% on year to INR 8.47 billion, while the contract research, development, and manufacturing organisation segment saw muted revenue growth of 1.8% to INR 10.37 billion. Biocon's biosimilars segment's revenue, however, increased 12% on year to INR 27.56 billion.

The company reported consolidated earnings before interest, taxes, depreciation, and amortisation of INR 10.73 billion for the March quarter against INR 11.15 billion in the year-ago quarter. The company's EBITDA margin for the reporting quarter came at 23% against 25% a year ago. The company's research and development expenses for the quarter were INR 2.77 billion, up from INR 2.31 billion a year ago.

Segment profits, according to Biocon, were also hit in two of three segments. The generics segment reported a loss before tax of INR 123 million for the March quarter as compared to a profit of INR 1.81 billion in the year-ago quarter. The contract research, development, and manufacturing organisation segment reported a 16% on-year fall in profit before tax to INR 2.02 billion, while biosimilars segment's profit rose nearly 90% on year to INR 1.48 billion.

Biocon's consolidated net profit for 2025-26 (Apr-Mar) was INR 3.86 billion as against INR 10.13 billion in the previous year. The company's consolidated revenue for FY26 was INR 169.27 billion, up from INR 152.62 billion in FY25.

The company announced its March quarter and FY26 earnings on late Thursday. It also announced a final dividend of INR 0.50 per share, with Jul. 3 fixed as the record date. Shares of Biocon closed 0.4% higher at INR 382.25 on Thursday on the National Stock Exchange.  End

Edited by Vandana Hingorani

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.